BURLINGTON, Mass., Jan. 29, 2013 /PRNewswire/ -- inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services, today announced a realignment of its global communications division to better respond to client demand for unified, worldwide communications services. With a network of 1,800 professionals, inVentiv Health Communications (iHC) is ranked by Advertising Age as the world's second largest healthcare agency network.
iHC will operate under a "Done as One" model that enables the convergence of inVentiv's advertising, public relations, public policy, market access, medical communications, media, creative, branding, and digital services.
"The integration of our communications division is another important step in the evolution of our business strategy designed to deliver all of inVentiv's capabilities seamlessly to the client," said Paul Meister, Chief Executive Officer of inVentiv Health, Inc. "In this highly challenging environment, our clients are looking for innovative solutions and this model allows us to more efficiently meet their needs." Meister added that inVentiv has appointed Bob Chandler to lead the newly realigned division.
Chandler will serve as iHC's worldwide President while remaining actively involved in the agency he founded, Chandler Chicco Companies. "By connecting these multidisciplinary agencies in what we're calling a 'Super Agency' structure, we offer enormous presence in healthcare and unrivaled perspective on the sector and its future," said Chandler. "Our goal is to support clients who must quickly maneuver in a complex world where media are ubiquitous, consumers are in the driver's seat and healthcare is swiftly transforming."
Joining the newly aligned team is Rob Quish, who serves as iHC's President of Global Strategy. Quish has played an instrumental role in the agency's realignment and will focus on enhancing creativity, innovation and collaboration across iHC. He previously held a variety of senior management positions with global advertising agencies, such as J. Walter Thompson Company and Lowe & Partners.
The new convergent services model allows clients to bring their challenge to iHC, which then assembles the cross-disciplinary expertise, services and team needed to succeed. The client-centric team operates with a single point of contact and financial administration. Such seamless, strategic collaboration leads to services that are nimble, flexible and targeted to provide global clients with the support required in a fiercely competitive marketplace.
For the past year, iHC has successfully operated under this model in Europe and China, delivering exceptional, global, multichannel results. In the United States, iHC is composed of a group of well known specialist agencies respected for their high level of expertise.
- Within the advertising discipline, as part of the U.S. realignment, four agencies are combining to create two digitally driven agencies singularly focused on health engagement. Palio and Ignite Health become Palio+Ignite and GSW Worldwide with Blue Diesel become GSW Worldwide, Fueled by Blue Diesel.
- Additional expertise to support inVentiv Health Communications agencies comes from three new centers of excellence: inVentiv Creative Studios, providing full-service design, creative and technology capabilities; inVentiv Digital+Innovation, offering global digital strategic solutions, technology platforms and thought leadership; and inVentiv Media 360°, a specialized healthcare media agency providing integrated multichannel communications strategies and media solutions.
- Existing best-in-class inVentiv Communications' brands include Addison Whitney, a brand consulting firm; Chandler Chicco Companies, a multiservice global public relations group; The Navicor Group, a full-service marketing communications firm focused on oncology and immunology; Patient Marketing Group, focused on innovative patient relationship marketing programs; and inVentiv Medical Communications, a global network of specialists and agencies delivering full-service medical communications and education.
Clients have the option of accessing individual agency services as before, through their existing agency, or the entire iHC network of seamless services across many more communications disciplines.
By connecting iHC's multidisciplinary agencies to inVentiv's clinical and consulting services, iHC can offer deeper strategic solutions across the health and wellness spectrum in a way that cannot be matched by any other agency in the industry.
About inVentiv Health Communications
inVentiv Health Communications (iHC) is the inVentiv Health division dedicated to delivering exceptional, global, multichannel communications to organizations focused on health and wellness. The company's unified offer brings together inVentiv Health's advertising, public relations, public policy, market access, medical communications, media, creative, branding and digital services creating a "Super Agency" structure. iHC provides relevant, targeted and flexible marketing solutions for the pharmaceutical industry and organizations with a healthcare focus, enabling clients to excel in a rapidly changing environment.
About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv's 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced and future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the impact of customer project delays and cancellations; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.
SOURCE inVentiv Health, Inc.